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Steroids in Arms:
Science, Government, Industry, and the Hormones
of the Adrenal Cortex in the United States,
1930-1950
NICOLAS RASMUSSEN*
Experimental life science in the twentieth century is aptly characterized as a quest
for "master molecules", biochemical entities presumed to govern all basic vital
processes and phenomena. Today many commentators critique the reigning "genetic
essentialism"-the notion that everything about the life ofhuman beings (and other
living things) is predetermined in their DNA, today's master molecule.' However,
notwithstanding efforts by early geneticists to promote the gene, present fashion
must not make us forget that in the first half of the twentieth century, hormones
tookprideofplace aslife's mastermolecules, andtheendocrinologist tookprecedence
over the geneticist as the scientist offering the means to control life. For such are
the inherent implications of master molecules: to discover and manipulate these
substances is to acquire the means to control the vital processes and phenomena
governed by them. The master molecule thus constitutes an intersection between
intellectual, therapeutic, and commercial interests, naturally attracting the most
ambitious participants in biomedical science and industry. And indeed, many ethical
pharmaceutical companies in the inter-war era-driven in the United States and
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other countries by a medical profession eager to shed old nostrums for new
remedies bearing the stamp of laboratory science-did bring a remarkable variety
of(comparatively) purehormone preparations tomarket for anevenmore remarkable
range ofclinical indications. In the process, drug firms avidly supported the hormone
research ofleading physiologists and biochemists, forging new ties between academic
life science and biomedical industry that helped shape the future development of
pharmaceuticals.2 Since the power and promise extravagantly attributed to genes
today echo those surrounding hormones half a century ago (not to mention the
advantages and drawbacks of the scientist-industrialist collaborations created to
harness the power of life's master molecules), we may have much to learn from
studying earlier endocrinological dreams.
To help recapture the heady atmosphere of medical, scientific and commercial
enthusiasm surrounding hormones in the first half of the twentieth century, and the
scientist-industrialist collaborations it spawned, in the following essay I trace Edward
C Kendall's research on the hormones of the adrenal cortex in the 1930s and 1940s.
This story illustrates well all three aspects of endocrine research in the period noted
above: the nearly unlimited power over life processes ascribed to hormones; the
immense medical and commercial promise perceived to lie in hormones; and the
intimate interactions between top-level life scientists and the drug industry in the
inter-war period generated by the effort to bring hormone therapeutics to market,
which continued right through the war despite the strong involvement ofgovernment
science agencies. Because the concluding part of the story, in which the American
government organized and sponsored a crash programme to develop the cortical
hormones as performance-enhancing drugs for combat pilots, may throw new
light on the nature of state management of life science and industry during the
war, it will be treated in particular detail. I argue that, in this field of biomedicine
at least, the discontinuities in the practice of research introduced by war were
not so great as envisioned by commentators who see the Second World War as
a watershed for American science, proposing, for instance, that the larger
government-sponsored projects set new precedent by "transgressing and reshaping"
"boundaries ... between public knowledge and private profit" and bringing "Big
2John P Swann, Academic scientists and the 1982; Nelly Oudshoorn, Beyond the natural body:
pharmaceutical industry: cooperative research in an archaeology ofsex hormones, London,
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industry, Baltimore, Johns Hopkins University University Press, 1987. See also Nicolas
Press, 1987. On hormone drug development see Rasmussen, 'Biotechnology before the "biotech
Alison Li, 'J. B. Collip, A. M. Hanson and the revolution": life scientists, chemists and product
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endocrines and enterprise', J. Hist. Med Allied Reinhart (ed.), Chemical sciences in the 20th
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Science" to life science as well as physics.3 On the contrary, the scientific, medical
and commercial promise of the master molecules had already made endocrinology
into "Big Science" before the war, and wartime government involvement in the
field did little to change this.
The Hormone Business in America, 1900-1930
From the late nineteenth century to the 1940s, endocrinology was one ofthe most
dynamic areas of biomedical research, despite a certain aura of quackery that
gathered around the field in its earliest years, generated precisely by its perceived
promise (which provoked a proliferation of unrefined organ extract treatments for
popular ailments such as impotence and hysteria). Together with bacteriology,
endocrinology was one of the first areas in which the life sciences established their
direct utility in clinical medicine, with the milestone 1891 demonstration that extract
ofthyroid glandswaseffective intreatingthewell-definedclinicaldeficiency condition
myxoedema. By the 1920s, a high calibre of laboratory research had elevated the
stature of the field, and a standard pattern for hormone research programmes had
coalesced. Typically, a deficiency condition was created in an experimental animal
(ideally, a condition with clear similarities to a human disease) by surgical removal
of an endocrine organ, and then chemical extracts ofthe organ were prepared from
slaughterhouse waste or other abundant sources and tested for their capacity to
remedy the experimental animals' condition. Testicular extract was tested for its
ability to promote comb growth in capons, for example, and pancreatic extract for
its ability to prevent diabetic symptoms in dogs whose pancreas had been excised.
Once a preparation procedure was developed that yielded extracts active in treating
the deficiency condition ofthe experimental animals, efforts turned to concentrating
and purifying the active compound(s) by chemically fractionating the organ extract,
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at every step using bio-assay with the experimental animals to detect the fraction
containing hormone activity. Success was marked by crystallization ofa pure, highly
active compound presumed to be the native hormone on the basis of its full
substitution, in the experimental animals, for the gland removed. Analysis of the
hormone'schemical structure andproperties followed, and, iftechnologically feasible,
the analysis would be confirmed by chemically synthesizing a compound of the
proposed structure and showing the synthetic material to have hormone activity
identical to natural organ extracts in the standard bio-assay. The growing chemical
sophistication of endocrinology research brought biochemists into ever-closer col-
laborations with physiologists, or else into physiological research themselves. Indeed,
such work in endocrinology was a major driving force in the development of
biochemical methods, andin the rising status ofbiochemistry, duringthefirstdecades
of the twentieth century.4
The typical trajectory of hormone research just outlined constituted not only a
programme for the advancement of biomedical knowledge during the inter-war
years, but simultaneously a plan for commercial drug development. As noted, from
the earliest days ofendocrinology, more or less active extracts ofa variety oforgans
weremarketed forusebyphysicians: mostnotoriouslytestesextractsforthetreatment
offlaggingvirility, butalso extracts ofovaries, pancreas, thyroidglands, andadrenals.
From 1897 to 1901, the blood-pressure-raising hormone epinephrine was isolated
from adrenal glands, and was quickly brought to market in relatively pure form
with great success by Parke-Davis Company, under its trade name "Adrenaline". In
1915, chemically pure thyroid hormone highly active in treatment of myxoedema
was isolated, and soon founditsway into themarketplace for avariety ofconditions.5
The 1922 advent of insulin, saving millions of diabetics from the prospect of early
and lingering deaths, vividly confirmed the medical and commercial potential of
endocrinology, and raised the competitive tempo of the field. The drug had been
developed through a mutually profitable collaboration between the Eli Lilly firm
and the University ofToronto, site ofthe crucial research on isolating the pancreatic
hormone. Lilly's spectacular success brought many other drug companies into closer
collaboration with enterprising endocrinologists in an effort to repeat the insulin
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story with the hormones of other organs, and even spurred the establishment
of whole new endocrine firms, such as Organon in Holland. In these growing
collaborations between pharmaceutical companies and academic life scientists in
hormone research (and in the neighbouring field of vitamins), drug firms sought
access to novel scientifically validated therapeutics, and the scientists garnered
material assistance for their research. The level ofhormonal enthusiasm among drug
firms and enterprising scientists prompted at least one contemporary commentator
to describe this situation in endocrinology ofthe 1920s and 1930s as a "gold rush".6
On both the biochemical and commercial fronts of endocrinology, Edward C
Kendall ofthe Mayo Clinic and Foundation could safely be described as a trailblazer.
For three years after his 1910 Columbia University doctorate in chemistry, received
at the age of twenty-four for work on a starch-degrading enzyme isolated from
pancreas, Kendall had struggled against a widespread attitude of physicians and
drug firms alike that biochemists were suited only to service roles. Finding a haven
at the Mayo Clinic in 1914 as head of that institution's new biochemistry section,
Kendall proved his vision that biochemical research could advance practical thera-
peutics with the crystallization ofthe thyroid hormone, named "thyroxine" by him,
within his first year there. The discovery was trumpeted in the press as a medical
triumph, bringing prestige to the Mayo and elevating Kendall's scientific reputation.
In 1916, well before his definitive 1919 paper on the chemical attributes ofthyroxine,
Kendall had patented his thyroid hormone preparation method and assigned this
intellectual property to the University of Minnesota, which had affiliated with the
Mayo Clinic when the two entitiesjointly established the Mayo Foundation in 1915
as a (non-profit) teaching institution ofthe University's medical school. In 1919, the
University granted an exclusive licence for use of Kendall's patent to the Squibb
pharmaceutical firm in exchange for 50 per cent ofprofits from the product, which
Squibb successfully marketed. Kendall's thyroxine and other less pure thyroid
hormone preparations became popular drugs in the inter-war years, not just for
myxoedema and other hypothyroid conditions, but also, because of their general
metabolism-stimulating effects, for a wide range ofdisorders including constipation,
menstrual disorders and even for weight control in "those who enjoy food to the
extent that obesity is preferable to self-denial".7
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The royalties to the University of Minnesota from Kendall's thyroxine patent
were placed in a special fund for Kendall to draw on for research expenditures. This
arrangement seems to have satisfied all parties, and was widely considered a success,
representing, perhaps, the triumph of the utilitarian ethic of chemists over the
Hippocratic ideals ofphysicians. In 1922, when Toronto physiologist J J R Macleod
sought Kendall's advice on whether to patent the insulin preparation procedure
developed by Frederick Banting, Charles Best, and James Collip in his laboratory,
Kendall explained the thyroxine arrangements, and offered Macleod his business
and ethical advice as well ("I can see no more reason why the man that separates
the active constituent of the pancreas should not share financially as much as the
man that makes a new wireless telephone"). As noted, the Toronto group did patent
their insulin production method, granting Lilly an exclusive licence for a limited
period to compensate the firm for its investment in the development of the drug.
The biochemist Harry Steenbock of the University of Wisconsin also emulated
Kendall, establishing a separate foundation when the University refused to manage
his vitamin D preparation patent directly.8 Kendall's thyroxine invention and patent
arrangements served as a paradigm of entrepreneurial life science in the inter-war
period, showing how a medical investigator might benefit his own research and his
institution, while at the same time benefiting mankind by ensuring that his discovery
was manufactured and distributed by a reputable drug firm, in conformity with the
highest quality standards.
The Biochemist-Entrepreneur Faces the Great Depression
For severalyears afterhis decade-long quest to prove the structure he had proposed
for thyroxine was foiled by a competitor in 1926, Kendall's research wandered among
several short-term projects. However, in 1930 he set his sights on a new major
objective: purifying and characterizing the hormone of the adrenal cortex, with an
eye to discovering a commercially feasible production method along the way. Belief
in an essential hormone of the adrenal cortex, as opposed to the adrenal medulla
from which epinephrine had been isolated at the turn ofthe century, was surprisingly
new at this point. It was not until the late 1920s that accumulating evidence began
to convince the medical profession that epinephrine was not an effective treatment
ofAddison's disease, the deadly condition caused by acute adrenal insufficiency, and
iodine compound which occurs in the thyroid', e.g. Louis Goodman and Alfred Gilman, The
J. Biol. Chem., 1919, 39: 125-47; idem, Thyroxine, pharmacological basis oftherapeutics, New York,
note 5 above. Also, the 1919 (otherwise n.d.) Macmillan, 1941, pp. 1156-69, quote on p. 1168.
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application 102,302 of 7 June 1916, carton 8, research: Harry Steenbock and the Wisconsin
folder 'Patents-Thyroxin', E C Kendall Papers, Alumni Research Foundation', Isis, 1989, 80:
Princeton University Archives collection c0669 375-94. For a brief contemporary account of the
(henceforward, Kendall Papers). For the uses to medical patent situation, see Morris Fishbein,
which thyroid hormone was put in the inter-war 'Medical patents', J. Am. med. Ass., 1937, 109:
years, see medical textbooks of the time, 1539-43.
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thus that a different hormone from the adrenal cortex might be involved. Between
1927 and 1930 several physiologists confirmed that adrenal extracts could indefinitely
sustain otherwise short-lived adrenalectomized dogs and cats, suggesting that such
animals could be used as a bio-assay for cortical hormone activity.9 These physio-
logical findings coincided with the Mayo visit, from late 1929 to early 1930, of the
eminent biochemist Albert Szent-Gy6rgyi, pursuing the isolation ofvitamin C from
adrenal glands obtained from slaughterhouses in nearby St Paul. Szent-Gy6rgyi
familiarized Kendall with work on the adrenal while there, and left behind some
large meat presses and other preparatory equipment. From his earlier thyroxine
triumph, Kendall was, of course, generally adept at the art of purifying scarce
hormones from ground animal tissue. Thus in terms of timing as well as local
intellectual and material resources, novel adrenal hormones emerged as especially
opportune scientific targets for Kendall in 1930. Moreover, Mayo's chiefofmedicine,
the physiologist and physician Leonard Rowntree, was conducting clinical research
on Addison's disease, and was eager to enlist Kendall's help in making adrenal
extracts so that he might try the new treatment on the many terminal Addison's
patients he had accumulated at the Mayo. Naturally, in the darkest days of the
Depression, biochemistry research with such direct clinical applicability was easiest
to justify at a resource-strapped medical institution. Thus a confluence of scientific
and social circumstances led Kendall quickly to refocus almost all his research on
the adrenal cortex.'0
Unfazed by his late start and by inevitable setbacks, including one premature
claim to have isolated and chemically identified the hormone of the adrenal cortex
which turned out to be an impurity from the benzene used in his extraction process,
in early 1934 Kendall became the first to achieve crystallization ofa hormone capable
of maintaining adrenalectomized animals. Kendall thus pushed to the forefront in
a crowded contest to bring a cortical hormone to the medical marketplace, a race
which included among the more formidable contenders thephysiologistWW Swingle
and his collaborators at Princeton, the pharmacologist Arthur Grollman of Johns
Hopkins, the Ohio State group of physiologist Frank Hartman (one of the 1927
discoverers ofactive adrenal extracts), and the biochemists Osker Wintersteiner and
J J Pfiffner (earlier of Swingle's group) at Columbia University. As early as 1931,
9See 0 Brenner, 'Addison's disease with exp. Biol. Med., 1927, 25: 69-79; F A Hartman
atrophy of the cortex of the suprarenals', and K A Brownell, 'The hormone of the
Q. J. Med, 1928, 22: 121-44; J M Rogoff and adrenal cortex', Science, 1930, 72: 76;
G N Stewart, 'The influence of adrenal extracts W W Swingle and J J Pfiffner, 'The revival of
on the survival period of adrenalectomized comatose adrenalectomized cats with an extract
dogs', Science, 1927, 66: 327-8; idem, 'Studies of the adrenal cortex', Science, 1930, 72: 75-6.
on adrenal insufficiency. IX. The influence of On the confusion between the effects of
extracts of adrenal cortex (sheep and cattle) on epinephrine and the hormones of the adrenal
the survival period of adrenalectomized dogs cortex, see Thorn, op. cit., note 5 above, and
and cats', Am. J. PhysioL, 1929, 91: 254-66; Robert Tattersall, 'Hypoadrenia or "a bit of
F A Hartman, C G Macarthur and Addison's disease"', Med Hist., 1999, 43:
W E Hartman, 'A substance which prolongs 450-67.
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Kendall had been deliberately developing extraction methods for cortical hormones
which simultaneously permitted good recovery of epinephrine from the adrenal
medulla, in order that sale of this by-product might defray a major part of the
expenses ofhis research programme. In the wake of his crystallization breakthrough
and the increased standing it brought, in 1934 Kendall approached the president of
Parke-Davis, which (as noted above) had built a lucrative trade in its name-brand
"Adrenaline" preparation, with a proposition to supply the firm with epinephrine
on an industrial scale in exchange for a continuous supply of adrenal glands. Parke-
Davis agreed to provide 500 pounds per week of fresh frozen adrenals to Kendall's
laboratory at the Mayo ifKendall would deliver epinephrine in the quantity normally
yielded, and meeting the firm's standards of purity. Epinephrine exceeding the
expected yield could be sold for cash by Kendall. In order to hedge against possible
costs incurred if he were not to meet his yield benchmark, the enterprising Kendall
struck another bargain with Wilson Laboratories of Chicago, a pharmaceutical
subsidiary of the Wilson meat-packing firm which produced therapeutic organ
preparations. Wilson agreed to provide 300 pounds per week offresh frozen adrenals
in exchange for standardization of the potency of the firm's cortical extracts by
Kendall's Mayo group, which had refined the relevant bio-assays to a high degree.
Kendall tripled his technical staff so he could keep what he aptly called his "pilot-
plant factory" running around the clock in three 8-hour shifts, six days per week,
and his laboratory continued work on this scale for some thirteen years, processing
nearly two tons of adrenal glands per month when operating at capacity.1" Kendall
soon became the chief source of purified cortical hormones in North America, and
Mayo the leading site for clinical treatment ofadrenal insufficiency, although cruder
commercial extracts were available to clinicians everywhere.
Patients suffering acute Addison's disease present some ofthe following symptoms:
mental fatigue, a sense of weakness accompanied by measurable decline in aerobic
capacity and muscle strength, loss of appetite and wasting, declining blood volume
and flow rate associated with excess sodium excretion through the kidneys together
with potassium and urea retention in the blood. Death often comes when these
symptoms culminate in circulatory collapse. However, treatment ofthecomparatively
uncommon Addison's disease, which was growing ever rarer with the decline of its
chief cause, tuberculosis, does not suffice to explain the high level of scientific and
commercial interest in the hormones of the adrenal cortex. Many doctors and
physiologists reasoned that even in patients with functional adrenal glands,
Addison's-like symptoms such as muscular weakness, mental fatigue, or reduced
resistance to cold might be alleviated by cortical hormone therapy. And in short
order after the invention and 1931 commercial introduction of cortical extracts
" E C Kendall, 'A study of the suprarenal Clinic, 1933, 8: 392-5; E C Kendall, H L Mason,
gland', Proc. StaffMeetings Mayo Clinic, 1931, 6: B F McKenzie, C S Myers, and G A Koelsche,
296; idem, 'Studies on experimental suprarenal 'Isolation in crystalline form of the hormone
deficiency: a demonstration', Proc. StaffMeetings essential to life from the adrenal cortex', Proc.
Mayo Clinic, 1932, 7: 595-6; idem, 'Chemical StaffMeetings Mayo Clinic, 1934, 9: 245-8;
nature of the hormone of the suprarenal cortex Kendall, op. cit., note 6 above, chs 6-7, quote on
essential to life', Proc. StaffMeetings Mayo p. 62.
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Figure 1: Part of the "pilot plant factory" for extracting hormones from adrenal glands in
E C Kendall's laboratory, Mayo Clinic, mid-1930s. Processing capacity was at least 800
pounds of beef adrenals per week. (Princeton University Library, E C Kendall Papers.
Manuscripts Division.)
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effective in relieving the distress of Addison's patients, a raft of animal studies
and clinical reports did appear confirming all these same effects in relatively
healthy (non-adrenalectomized, non-Addisonian) organisms and people. With
cortical hormone injections, normal dogs were found to run much longer on
treadmills, "neurotic" but otherwise normal sheep werecalmed, and non-Addisonian
patients reported increased vitality, lifting of depression, improved digestion and
sharpervision. Somestrikingresultsintreatingmusculardystrophyandschizophrenia
were even reported.12
Proudly reviewing the first generation of such studies that had followed the
discovery of the hormone he had dubbed "cortin" at a meeting of the American
College of Physicians in February 1933, Hartman stressed the evidence for the
substance's activity in counteracting weakness and "asthenia" ofthe nervous system,
the muscular system, andthecirculatory system, aswell ascertain otherphysiological
problems such as "gastrointestinal instability" and low resistance to disease. Of
course, Addison's patients suffered such problems, but Hartman's main argument
was that marginal insufficiency of cortical function could underlie many similar
complaints in patients with intact adrenals, and thus that cortical hormone might
be a widely effective therapeutic. Since "asthenias which are unaccounted for by any
known cause canbe treatedwithcortinwithoutharm", itwas sensible for aphysician
to try a course ofcortical extract injection on any patient complaining ofirritability,
fatigue, indigestion, impaired sexual function, insomnia-or simply feeling "below
par"-in order to cure the complaint. If a patient responded, the cause of the
condition must have been adrenal insufficiency.'3 Cortical extracts proliferated in the
marketplace. For example, Harrower Laboratories offered one called "Adreno-
Spermin", advertising that since "stress-emotional, toxic, infective-must involve
the endocrines", these glands, and the body as a whole, needed stimulation with
cortical hormone therapy. And judging from some contemporary criticism of the
"tendency toward the widespread and indiscriminate administration of cortical
extract in small and infrequent doses to all those who are 'weary and heavy laden"',
such products based on Hartman's way ofthinking became popular among the lay
public and physicians in the mid-1930s. Expectations that ifcortical hormone could
improve strength, endurance, and circulation in acute Addison's patients it might
do the same in relatively healthy people, scientifically ill-founded as they may have
been, certainly help to explain the degree of interest in the hormone for both the
medical profession and the pharmaceutical industry. Indeed, the discovery that
Addison's patients could be kept alive on a controlled high-sodium, low-potassium
'2E Eagle, S W Britton, and R Kline, 'The glycerin extract of suprarenal cortex potent by
influence of cortico-adrenal extract on energy mouth on schizophrenic patients',
output', Am. J. Physiol., 1932, 102: 707-13; Endocrinology, 1933, 17: 29-35. For neurotic
F A Hartman and G W Thorn, 'The effect of sheep, see F A Hartman, 'Studies on the
cortin in asthenia', Proc. Soc. exp. Biot. Med., function and clinical use of cortin', Ann. Int.
1931, 29: 48-50; Ralph Mendelson, 'Cortin in Med., 1933, 7: 6-22, p. 7.
the treatment of progressive muscular '3Hartman, op. cit., note 12 above, p. 18, for
dystrophy', J. Am. med Ass., 1934, 102: 604; R sex drive, insomnia, and "below par" feeling, see
G Hoskins and H Freeman, 'The effects of p. 8.
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diet with only occasional cortical extract did little to reduce interest in the hormone,
confirming that the treatment ofAddison's disease was not the driving force behind
these projects.'4
The industrial scale of his hormone purification effort served Kendall well not
only in his race with local competitors, but also with his outstanding European rival,
the chemist Tadeus Reichstein of Switzerland. Reichstein was collaborating with
Organon, which from Holland supplied the large batches of adrenal extracts that
served as the essential raw material of all such research, and in return received
Reichstein's patents for improved extract preparation methods. In addition, the
Amsterdam group of Organon's co-founder, the physiologist Ernst Laqueur, col-
laborated with Reichstein by handling bio-assay work on the hormone preparations.
Laqueur's research group, and all the others involved, each used different assays to
gauge the activity of their cortical preparations. For example, some researchers
favoured rate of weight gain in adrenalectomized juvenile rats as an index of
cortical hormone activity; some a restoration of glycogen stores in the liver of
adrenalectomized rats or other animals; some favoured reduction ofincreased blood
urea levels in adrenalectomized dogs; some used the capacity of adrenalectomized
rats to swim. Kendall relied upon the capacity of a muscle in an immobilized,
anaesthetized, adrenalectomized rat to perform work over hours or even days,
together with a test employed by most groups, the dose required to support
adrenalectomized dogs (Kendall's dogs, however, were individually "calibrated"
with carefully controlled diets and known sensitivity to cortical extracts).'5 Thus
each of the bio-assays measured cortical hormone activity by improvements in
physiological indicators corresponding to particular Addison's-like symptoms in
animals with "experimental adrenal insufficiency" (i.e. total adrenalectomy): those
measuring blood nitrogen and electrolyte concentrations primarily gauged what
Hartman called "circulatory asthenia"; those measuring glycogen stores and
activity performance gauged Hartman's "neuro-muscular asthenia". And within
these two general classes of assays, procedures differed more or less subtly among
the laboratories.
The level ofcompetition in the race to identify and produce the cortical hormone,
together with the variety of assays employed by this research community, had led
14Adreno-Spermin advertisement in Am. J. cortex: general, carbohydrate and circulatory
med Sci., November 1935, 189: 11. G A Harrop, theories', Am. J. Physiol., 1934, 107: 190-206;
Albert Weinstein, L J Soffer, and J H Threscher, J J Pfiffner, W W Swingle and H M Vars,
'The diagnosis and treatment of Addison's 'The cortical hormone requirement of the
disease', J. Am. med. Ass., 1933, 100: 1850-5; adrenalectomized dog, with special reference to
R F Loeb, 'The effect of sodium chloride in a method of assay', J. Biol. Chem., 1934, 104:
treatment of patients with Addison's disease', 701-16; D J Ingle, 'Work capacity of the
Proc. Soc. exp. Biol. Med., 1933, 30: 808-12; adrenalectomized rat treated with cortin', Am.
idem, 'Glandular physiology and therapy: the J. Physiol., 1936, 116: 622-5; Kendall, op. cit.,
adrenal cortex', J. Am. med Ass., 1935, 104: note 6 above, ch. 7. For an example of the
2177-82, quote on p. 2182. patents Reichstein assigned to Organon, see
'5Arthur Groilman, The adrenals, Baltimore, 'Hormone compositions', German patent 656,
Williams and Wilkins, 1936; S W Britton and 785 of 19 February 1938, cited in Chemical
H Silvette, 'On the function of the adrenal Abstracts 1938, 32: 4287.4.
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initially to controversy over the true role of "the hormone" of the adrenal cortex.
However, in the mid-1930s, the dispute over whether cortin was a "general tissue
hormone" stimulating all cell types (as Hartman thought), or a hormone specifically
controlling the balance of fluid and mineral electrolytes in tissue, or a hormone
specifically regulating carbohydrate metabolism, began to give way to a realization
that the adrenal cortex might control a variety of distinct physiological functions
through several different hormones. In 1937 most attention was focused on the
effects of cortical hormones on mineral metabolism (i.e. sodium and potassium in
blood and other fluids) and its influence on circulatory collapse through fluid loss.
Indeed, at a Cold Spring Harbor symposium that year all the major players,
including Kendall, seemed prepared to accept that the adrenal cortex's influence on
carbohydrate metabolism was merely a secondary effect of cortin's influence on
minerals, or else the effect of another cortical hormone not essential for life.
The one dissenter still insisting on the primacy of carbohydrate metabolism, and
particularly the dependence ofblood glucose and glycogen stores on cortical activity,
the physiologist S W Britton of the University of Virginia medical school, met with
general scepticism there. A key reason for this scepticism lay in the failure ofcortical
extract to produce diabetes-like conditions in animals both adrenalectomized and
pancreatectomized (which, paradoxically, appeared to be spared diabetes by the
absence of the adrenals). However, later in 1937, the group of the Yale physiologist
Cyril Long was finally able to reproduce diabetes in such adrenalectomized-pan-
createctomized animals by using stronger extracts obtained from Kendall. Evidence
now supported a crucial role for the cortical hormone (or one of these hormones)
in carbohydrate metabolism."6
In that same year, 1937, Reichstein stunned his competitors with a barrage of
papers describing a variety of active compounds isolated from extracts provided by
Organon, one of which he dubbed "corticosterone" in the expectation that the
hormone, which affected sugar as well as mineral metabolism to some extent, was
either Hartman's long-sought cortin or a close relative. His group also achieved
synthesis ofthe related compound desoxycorticosterone, with a much higher activity
on mineral metabolism than his corticosterone, by a commercially practical method.
Clinical trials soon demonstrated that desoxycorticosterone did effectively maintain
the life of Addison's patients in the same way as dietary control of minerals,
but did not relieve lassitude and other symptoms associated with carbohydrate
metabolism. Together with Long's results, these findings left little doubt that the
hormonesoftheadrenalcortexactiveinmineralmetabolismandinenergymetabolism
were distinct. And, since desoxycorticosterone did not fulfil this other, energy-related
role ofthe cortex, another hormone drug still remained to be developed. Presumably
this elusive hormone, active in regulating carbohydrate metabolism, would be a
"See articles and discussions on adrenal and adrenal glands upon pancreatic diabetes',
hormones in Cold Spring Harbor Symp. Harvey Lect., 1936-37, 32: 194-228;
Quant. Biol., 1937, 5, especially S W Britton F D W Lukens and F C Dohan, 'The relation
and H Silvette, 'The adrenal cortex and of the adrenal cortex to experimental diabetes:
carbohydrate metabolism', pp. 357-61. further observations', Endocrinology, 1938, 22:
C N H Long, 'The influence of the pituitary 51-8.
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compound with an oxygen on carbon 11 of the steroid nucleus, like Reichstein's
corticosterone and the cortical hormone Kendall called Compound E."7
At this stage, however, Kendall's closest American competitors seem to have
accepted defeat in the face of Reichstein's chemical prowess, Pfiffner departing
Columbia for an industrial position at Parke-Davis and Wintersteiner for one at
Squibb. This left Kendall, in 1938, Reichstein's major academic opponent in the
contest to identify and produce the cortical hormone responsible for carbohydrate
metabolism. Reichstein was trying to synthesize his corticosterone, and presumably
was well advanced in this effort. But Kendall did not share Reichstein's opinion that
corticosterone, the same substance that Kendall called Compound B, was the chief
adrenal hormone affecting carbohydrate metabolism. The sense that Reichstein was
backing the wrong horse, together with information leading him to believe that
Reichstein would not be able to maintain the pace of his work on natural cortical
hormones because Organon would not be continuing to supply him with extracts so
generously, gave Kendall enough confidence to continue his focused quest for
Compound E-his best guess as the cortical hormone regulating carbohydrate
metabolism. This was the hormone which enhanced, at least in experimental animals
made deficient in adrenal function, the capacity ofmuscles to perform work and the
production ofbody heat in response to cold, which made respiration more efficient,
and which possibly could combat shock through an effect on capillary oxygen
exchange (as well as throughwhatever mineral activity the hormone mightpossess).'8
"For some of Reichstein's publications at this
time, see P de Fremery, Ernst Laqueur, Tadeus
Reichstein, R W Spanhoff, I E Uyldert,
'Corticosteron, a crystallized compound with the
biological activity of the adrenal-cortical
hormone', Nature, 1937, 139: 26; Tadeus
Reichstein, F Verzar, and L Laszt, 'Activity of
corticosteron in the glucose test in rats', Nature,
1937, 139: 331; Marguerite Steiger and Tadeus
Reichstein, 'Partial synthesis of a crystallized
compound with the biological activity of the
adrenal-cortical Hormone', Nature, 1937, 139:
925-6; Tadeus Reichstein, 'Constituents of the
adrenal cortex. X. corticosterone', Helvetica
Chimica Acta, 1937, 20: 953-69; Marguerite
Steiger and Tadeus Reichstein, 'Chemical
structure ofcorticosterone', Nature, 1938,
141: 202. For clinical results with
desoxycorticosterone, see S Levy Simpson,
'The use of synthetic desoxycorticosterone acetate
in Addison's disease', Lancet, 1938, ii: 557-8;
E P McCullagh, 'Sodium and chloride retention
in Addison's disease treated with
desoxycorticosterone acetate', Cleveland Clin. Q.,
1939, 6: 105-8; G W Thorn, R P Howard, K
Emerson, Jr, and W M Firor, 'The treatment of
Addison's disease with pellets ofcrystalline
cortical hormone (synthetic desoxy-corticosterone
acetate) implanted subcutaneously', Bull. Johns
Hopkins Hosp., 1939, 64: 339-65; H W Dryerre,
'The effect ofdesoxycorticosterone acetate and
cortin on salt elimination in Addison's disease',
Br: med J., 1939, i: 971-3; J W Ferrebee,
C Ragan, D W Atchley, and R F Loeb,
'Desoxycorticosterone esters, certain effects in the
treatment ofAddison's disease', J. Am. med Ass.,
1939, 113: 1725-31. For some of Kendall's views
of the relation ofadrenal hormone structure and
function at this time, see E C Kendall, 'Chemical
studies of the adrenal cortex: the structures of
compounds C, D, E, F, and G', J. Biol. Chem.,
1938, 124: 459-74.
" Kendall, op. cit., note 6 above, chs 7-8. On
oxygen consumption and muscle work see Ingle,
op. cit., note 15 above; F A Hitchcock,
R C Grubbs, and F A Hartman, 'The effect of
cortical extract upon oxygen consumption of
normal human beings', Am. J. Physiol., 1938,
121: 542-8; V Missiuro, D B Dill, and H T
Edwards, 'Effects ofcortical extract in rest and
work', Am. J. Physiol., 1938, 121: 549-54;
D J Ingle, 'The work-performance of
hypophysectomized rats treated with cortin', Am.
J. PhysioL, 1938, 122: 302-5. On heat generation,
see S M Horvath, F A Hitchcock, and
F A Hartman, 'Response to cold after reduction
of adrenal tissue', Am. J. Physiol., 1938, 121:
178-84; S M Horvath, 'Response to cold
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Hormones at War
Physiological properties like these carried medical implications which, with the
fall of France in May 1940 and the escalation ofthe air war over Britain, suddenly
took on great military significance. In October 1940, the National Research Council
(NRC) Committee on Aviation Medicine was formed to advise the United States
military, one ofmany such committees through which the United States government
enlisted the aid of scientists to advise the military. Among the first investigations
initiated by this Committee was one led by George Thorn, then an energetic young
endocrinologist and clinical researcher at Johns Hopkins, to follow up on early
reports of the adrenal gland's involvement in adaptation to high altitude. Thorn
found that in humans and animals made to perform prolonged work in low-oxygen
environments, blood sugar increased after several hours and performance was
thereforemaintained,whereasno suchresponseoccurredinadrenalectomizedanimals
(consistent with prior results that animals living in low oxygen atmospheres had
hypertrophied adrenal glands). This suggested that adrenal hormones affecting
carbohydrate metabolism were a key factor in the adrenal gland's role in adaptation
to high altitude. And high altitude was an absolutely crucial factor in the air war,
as improved aircraft technology and the demands of aerial combat were suddenly
thrusting large numbers ofpilots to unprecedented heights. As one officer studying
the problems (fatigue, vision impairment, reflex slowing, etc.) arising from pilot
exposure to cold and low oxygen conditions of high altitudes aptly put it, "the
machine has far outstripped the man" in aviation.'9
In May 1941, a secret conference of leading endocrinologists and physiologists
was convened by the NRC at Yale to discuss the military potential of adrenal
research. John Fulton, a member ofthe Committee on Aviation Medicine, explained
the circumstances leading to this meeting in his introductory remarks:
Dr. Thorn submitted his first report on January 15, 1941 ... Meanwhile unconfirmed rumours
were being received from abroad that severe cases offlying stress among Germans and RAF
were being encountered, in which an Addison-like syndrome has appeared accompanied by
pallor, general malaise, fatigability, weakness etc. At about the same time it was learned that
the German Air Force, and possibly also the English, were using adrenal cortical hormones
to counteract fatigue, and possibly also in the treatment offlying stress ...
following double adrenalectomy', Endocrinology, 9Captain Charles Stephenson, minutes of
1938, 23: 223-7. On shock, see W W Swingle, OSRD Committee on Medical Research(CMR)
W M Parkins, A R Taylor and H W Hays, 'The meeting, 4-8 September 1941, pp. 40-41, box 12,
direct effect ofcortical hormone on blood folder26, A NRichardsPapers, University of
pressure in shock induced by intestinal PennsyvaniaArchives collection UPT50/R514
manipulation', Proc. Soc. exp. Biol. Med, 1937, (hereafter, Richards Papers). Minutesofthe
37: 601-4; idem, 'The effect of cortical hormone NationalResearch CouncilDivision ofMedical
upon circulatory collapse of adrenalin shock', Sciences conference on theadrenalcorticalhormones
Am. J. Physiol., 1938, 123: 668-76; idem, 'A study in relation tomedicaldefense, Yale Schoolof
of the circulatory failure and shock following Medicine, 16-18 May 1941, Washington, Office of
trauma to the healthy, vigorous, War Information, 1941 (available in the book
adrenalectomized dog', Am. J. Physiol., 1938, collection ofthe National Library ofMedicine,
124: 22-9. Bethesda, MD).
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A week or two ago, we had a confidential report from Buenos Aires that the German
Government hadjust purchased 50 tons ofadrenal tissue from the Argentine, which is being
shipped to Germany via Japan. We have, therefore, felt impelled to take energetic steps to
see in what direction adrenal extract may be useful to the aviator.20
Given the state ofphysiological knowledge about adrenal hormones, coinciding with
the early successes of Germany's Blitzkrieg and rampant speculations about the
secret weapons enabling it, tales ofNazis shipping adrenal glands by U-boat for use
by their pilots were understandably greeted with alarm rather than scepticism (ill-
founded though those tales later proved to be). In September 1941 the United States'
newlyestablishedwartime agencyforbiomedical research, theCommittee on Medical
Research (CMR) ofVannevar Bush's Office ofScientific Research and Development
(OSRD), took over much of the work of the Committee on Aviation Medicine
(which now acted, like many other NRC committees, in an advisory role to the
OSRD). Cortical steroids, and Kendall's Compound E in particular, became one of
the agency's top life science R & D targets for co-ordinated large-scale research
effort, along with penicillin, anti-malarial drugs, and the development of substitutes
for whole blood transfusions.2'
In early October 1941, at the request of CMR chiefAlfred Newton Richards, his
friend William Mansfield Clark, an eminent biochemist trusted by industry and
respected by academics (and chair ofthe NRC Committee on Chemistry), organized
a conference ofthe American researchers most closely involved in the development
of adrenal steroid hormones as drugs in order to assess the current status and
prospects. Attending were Kendall, Louis Fieser from Harvard, Everett Wallis from
Princeton, as well as Wintersteiner from Squibb and Pfiffner from Parke-Davis. All
these biochemists and endocrinologists played their cards close to their chests, but
20John Fulton, in Minutes, note 19 above,
p. 2. The faulty intelligence report on German
gland-smuggling has achieved mythic status
among steroid biochemists. It has been attributed
to the Polish underground (see Arthur J Birch,
'Steroid hormones and the Luftwaffe', Steroids,
1992, 57: 363-77), and has also been said, on the
basis of slightly more direct evidence, to have
emerged from the capture of a German
submarine en route from Argentina with a load
ofincorrectly identified liver, actually intended
for vitamin B12 research (see Louis F Fieser, The
scientific method: apersonal account ofunusual
projects in war andpeace, New York, Reinhold,
1964, pp. 159-62). I am aware of no evidence on
the source of the Allied intelligence more reliable
than these apocryphal stories.
2 CMRmeeting minutes, 11 Sept. 1941, folder
28, box 12, Richards Papers. On penicillin see
Jeffrey Sturchio, 'Chemistry in action: penicillin
production in World War II', Today's Chemist, Feb.
1988, pp. 20-2, 35-6; PeterNeushul, 'Science,
government, and the mass production of
penicillin', J. Hist. Med AlliedSci., 1993, 48:
371-95. On the role ofNRC committees in the
penicillin and otherCMRprojects during(and
indeed, after) thewar, see Harry Marks, The
progressofexperiment: science andtherapeutic
reform in the UnitedStates, 1900-1990, Cambridge
University Press, 1997, ch. 4, andpassim. On blood
substitutes, see Creager, op. cit., note 3 above.
Forcomprehensive treatment ofmedical research
under OSRD auspices, see E C Andrus, D W
Bronk, GA Carden, Jr, C S Keefer, J S Lockwood,
J TWearn, and M CWinternitz (eds), Advances in
militarymedicine, 2vols, Boston, Little, Brown,
1948-although this source coversvery little ofthe
cortical steroid research, which at the time of
writingwas considered a failure. On Bush and the
OSRD in general, see Dupree, op. cit., note 3
above; J P Baxter, Scientists against time, Boston,
Little, Brown, 1946; Irvin Stewart, Organizing
scientific researchfor war, Boston, Little, Brown,
1948; G Pascal Zachary, Endlessfrontier: Vannevar
Bush, engineer oftheAmerican century, NewYork,
Free Press, 1997.
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they agreed that Clark should receive full progress reports, including proprietary
knowledge, from all research teams and to decide when one ofthem had progressed
to the point where the others needed to be informed and redirected in order to
prevent needless duplication of effort. The group also concurred that the supply of
adrenal glands was insufficient to meet any but research needs, that the problem of
synthesizing a substance with an oxygen at carbon 11 ofthe steroid nucleus was the
key to making Compound E available on a commercial scale, and that they would
make work on this synthetic problem a top priority.22
Clark and Richards immediately began organizing more chemists to pursue the
synthetic production of Compound E (as described below), and in late 1941 the
CMR also initiated physiological research contracts on adrenal hormones, many
picking up work begun under NRC Aviation Medicine auspices. Gerald Evans of
the University ofMinnesota studied the impact ofprolonged anoxia in intactanimals
(especially mice), in particular carbohydrate metabolism, temperature change, and
morphological change in the adrenals, and also modifications of these impacts
through treatment with adrenal extracts. Thorn undertook studies of carbohydrate
metabolism and low pressure tolerance in a variety of experimental animals, some
without adrenal glands and some normal. Hartman investigated the distinct roles of
low atmospheric pressure and low oxygen on the adaptive responses of normal
animals to altitude, especially those mediated by the adrenals. Henry Ricketts ofthe
University ofChicago similarly studiedthedistincteffects ofanoxiaand lowpressure,
both prolonged and intermittent, on physiological changes in various organs of
normal animals. Rueben Gustavson ofthe University of Colorado tested the effect
of a wide range of steroids, including testosterone and estrogens, on the tolerance
of rats to low-oxygen, high-nitrogen atmosphere. E S Sundstroem of the University
of California tested the effects of intermittent and sustained anoxia on normal
animals' adaptation mechanism to high altitude, especially those involving the
adrenals, and the impact of adrenal extract treatments on these adaptations. And
Herbert Evans of the University of California adapted his existing research
programme to the war, studying the effects of his recently purified adreno-
corticotropic hormone, which the brain secretes and which stimulates the adrenal
cortex, on carbohydrate metabolism at various atmospheric pressures. All of these
projects were aimed at learning whether treatment of aviators with adrenal cortex
hormones would increase their tolerance for high altitude. In addition, several
contracts with physiologists were initiated to investigate whether cortical hormones
counteract traumatic or surgical shock.23 All this research was intended to assess
the utility to the military of Compound E, and thus the probable wartime
demand for the drug, if it proved technically and economically feasible to
manufacture in quantity.
22W M Clark, 7 Oct. 1941, 'Briefofthe 23See information sheets for OEM-cmr
Conference on Cortical Substance E', box 9, folder contracts 20, 43, 60, 64, 74, 113, 133, 134,
'Adrenal Cortex', U. S. National Archives, Record and 174, carton 12, folder 51, Richards
Group 227, Entry 165 (hereafter, USNA 227/165). Papers.
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Makingthedrugavailable inquantitywouldbe thejobofchemists and biochemists
with talents in synthetic work. Kendall quickly took a number of actions to
consolidate his leadership position in what was clearly going to become an even
more crowded field. Two weeks after the first chemists' meeting on cortical steroids,
Kendall informed Richards that he had successfully synthesized a key intermediate
to Compound E and asked ifthe OSRD had any interest in claiming an intellectual
property stake in this invention (as was typical in CMR projects). Kendall was told
that since he had made his invention without government funding, patenting itwould
be his decision alone. A meeting with Vannevar Bush and the National Academy
president Frank Jewett was immediately arranged in New York, whence Kendall
flew directly from Washington. There, Bush suggested that the Research Corporation
might be the best institution to manage Kendall's new patent. This non-profit agency
existed to manage patents arising from academic-industrialist collaborations, finding
industriallicenseesforpatentsandfunnellingroyaltiesbacktofieldsandtoresearchers
specified by the research institutions and firms involved, an arms-length method
allowing universities and other scientific institutions to draw financial benefits from
the fruits oftheir research without having to commercialize the products themselves.
Bush was perhaps thinking ofthe Research Corporation's recent handling ofvitamin
B patents, licensed to the Merck pharmaceutical house and made available to
medicine by the firm, to contemporary acclaim.24
In any event, Bush arranged a meeting that same evening between Kendall and
the Research Corporation's President Howard Poillon. A full weekend of meetings
with lawyers, business executives and research managers, and bureaucrats in New
York ensued. By the time Kendall returned to Minnesota the following Wednesday,
less than a week after telling Richards of his new results, a bargain had formally
beenstruckwhereinthe ResearchCorporationwouldapplyforandmanage Kendall's
patent (which was to be kept secret in the interest of national defence) in exchange
for assignment of the patent and half of any royalties, the other half to go
into Kendall's University of Minnesota "Thyroxine Fund". Because of established
relations with the Merck corporation (and probably Kendall's preference for this
firm overParke-Davis, who werecourting Kendall forhiscortical hormones), Poillon
had arranged that Merck would be the drug firm licensed to use Kendall's patents,
and to assist him in further development of methods for Compound E synthesis.
This arrangement sealed, Kendall then tried to convince Clark that there was no
good reason for the chemists working on cortical steroids ever to meet again, arguing
that although the first meeting had been necessary to take stock, the group would
never be able to work co-operatively because ofcommercial rivalry between Squibb,
Parke-Davis, and Merck, along with "scientific competition" between Wallis, Fieser,
and himself. Indeed, Kendall suggested that he had the problem well enough in
hand so that no other chemists or companies (besides Merck) need be involved at
24For examples of the Research Corporation's Human Values, 1987, 12: 50-62, and Nicolas
mediation between academic life scientists and Rasmussen, 'The forgotten promise of thiamin:
industry in the first half of the twentieth century, Merck, Caltech biologists, and plant hormones in
see C Weiner, 'Patenting and academic research: a 1930s biotechnology project', J. Hist. Biol.,
historical case studies', Science, Technology, and 1999, 32: 245-61.
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all. Though unable to persuade the OSRD that he and Merck should be allowed to
handle the project alone, Kendall did manage to keep his results secret from the
other chemists and firms involved, convincing Clark not to reveal his starting
material when he informed the others which Compound E intermediate Kendall had
synthesized, since this would make the pathway specified in new patent application
obvious. Kendall's argument was that if other chemists had to be involved by the
OSRD in Compound E synthesis, they should all work independently ofone another
so that multiple approaches would be fully explored. Kendall's sympathy with
corporate concerns over sharing proprietary information must have helped him
avoid some of the conflicts commonly experienced by other academic scientists of
his day arising from industrial sponsorship of their research.25
Thus through Kendall's initiative, supported by Bush and Richards, the other
half-dozen academic chemists working on Compound E synthesis under government
contracts were, like the drugfirms, all blind to one another's activities, except insofar
as the Chairman, Clark, deemed it necessary to pass information among them. In
late 1941 and early 1942, six of Kendall's most formidable rivals among academic
biochemists (Werner Bergmann at Yale, Britton at Virginia, Thomas Gallagher at
Chicago, C R Noller at Stanford, plus Fieser and Wallis) were all given contracts
to pursue the same objective, synthesis ofhis Compound E; also, Arthur Grollman
(ofWake Forest) undertook a contract to search for substitutes for cortical steroids,
that is, unrelated molecules with similar biological activity.26 The secrecy policy
meant that nobody other than Merck, Kendall's chosen partner, would be able to
build easily on Kendall's prior work to reach the common goal faster. One can
appreciate Kendall's concern that government involvement might translate into
dilution or appropriation of the scientific credit he hoped to win from synthesizing
Compound E-not to mention economic rewards. On this latter score at least,
Kendall was reassured that the academic researchers were bound by a standard
clause in their CMR contracts waiving all rights to intellectual property acquired
under contract projects, except at OSRD discretion. In contrast, the industrial
participants in the project, which not only included Parke-Davis and Merck but also
Schering (but not Squibb, which redirected its efforts to penicillin), took no money
from the OSRD and thus were not hampered by government contracts. Likewise,
Kendall himself was not prevented from taking patents (which would be assigned
25Clark, n.d. [c. 30 Oct. 1941], 'Memorandum industry, and the problems that could arise
of Conference of Morning of October 24, 1941'; from such arrangements, see John Servos,
Kendall to Clark, 3 Nov. 1941; also Kendall to 'The industrial relations of science: chemical
Clark, 24 Sept. 1941, all in folder 'Adrenal engineering at MIT, 1900-1939', Isis 1980, 71:
Cortex', box 9, USNA 227/165. On the 531-59, and idem, 'The knowledge corporation:
contractual arrangements, see Howard Poillon to A. A. Noyes and chemistry at Cal Tech,
Kendall, 28 Nov. 1941, and Poillon, draft letter 1915-1930', Ambix, 1976, 23: 175-86.
of understanding and draft patent assignment 26See information sheets for OEM-cmr
agreement re. U.S. patent application 420,486 of contracts 32, 42, 55, 70, 95, 106, and 168,
28 Nov. 1941, 'Cortex Hormones and Process folder 51, carton 12, Richards Papers. Fieser
of Making Same', 28 Jan. 1942, both in older soon became Kendall's ally, accepting a
'Research Corporation', box 8, Kendall Papers. consultancy role with Merck and exchanging
For some other contemporary examples of laboratory staff both with Kendall's Mayo
American academic scientists collaborating with group and Merck.
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to the Research Corporation and licensed to Merck under the bargain he had just
struck) on the results ofhis war work, since he took no government funding for his
already self-financing, quasi-industrial project at Mayo. The drug firms were ap-
parently comfortable with Kendall's arrangements but, not surprisingly, some ofthe
academic chemists were frustrated. For instance, Gallagher of Chicago considered
multiple independent efforts an inefficient arrangement attributable to Kendall's
egotism. Nor was Kendall unduly handicapped by the veil of secrecy over the other
chemists' actions that he had been so central in imposing; Merck's research director
Randolph Major informed him when Wallis ordered an intermediate from Merck
that was "quite different" from his own, and when Gallagher ordered one that
Kendall also was using.27
By mid-1943 the results ofthe first year and a halfofphysiological contracts were
available, and themilitary potentialofCompound Eunderwentaninterim assessment
by Richards and the CMR. The overallpicturewas one ofequivocalandunimpressive
evidence. The results of Thorn and Gerald Evans were rated highest in reliability
by Richards, and were given the most weight. Among other things, Thorn confirmed
that in monkeys and other animals, repeated exposure to anoxia and low pressure
equivalent to 20,000-27,000 feet of altitude, physiological adaptation was ac-
companied by enlargement ofthe adrenal glands. Thorn also found that the absolute
ceiling (i.e. point at which death on average occurred) of normal rats exposed to
low pressures equivalent to altitudes over 30,000 feet was indeed raised by Kendall's
extract; however, similar improvements in altitude tolerance could be obtained
simply by preconditioning animals in atmospheres equivalent to 18,000-26,000
feet, suggesting that a training regimen might substitute for hormone treatments.
Moreover, using rats on treadmills in low-oxygen conditions, Thorn found no
significant increase in the "work capacity" ofanimals treated with Kendall's extracts
(though this experiment was confounded by large variations in the individual rats'
propensity to perform "work"). Evans discovered that the degree of enlargement of
adrenal glands accompanying high-altitude conditioning did not correlate with the
actual altitude tolerance of animals, throwing the central role of the adrenal in
altitude adaptation into doubt. He also found that in dogs no adrenal extract
treatments ameliorated the decline in motor and visual performance brought on by
low atmospheric pressures, and that in mice Kendall's extract brought only a slight
27Major to Kendall, 3 Dec. 1941; Kendall contractors, see Clark to Richards, 9 Feb.
to Major, 24 Dec. 1942; Major to Kendall, 1942, folder 'Adrenal Cortex', box 9, USNA
7 March 1942; folder 'Merck and Company 227/165. Interestingly, the CMR contract patent
Correspondence 194142', carton 8, Kendall provisions were generally more stringent than
Papers. T F Gallagher to Clark, 11 March for other OSRD contracts; see Larry Owens,
1942, folder 'Adrenal Cortex', box 9, USNA 'The counterproductive management of science
227/165. On Parke-Davis's and Schering's in the Second World War: Vannevar Bush and
independent pursuit of cortical steroid synthesis the Office of Scientific Research and
during the war, see Poillon to Richards, Development', Bus. Hist. Rev., 1994, 68:
13 Nov. 1941, folder 'Research Corporation', 515-76, and Nicolas Rasmussen, 'Of "small
carton 8, Kendall Papers; also see Fieser, op. men", big science, and bigger business: the
cit., note 20 above. On intellectual property second world war and biomedical research in
restrictions applying to OSRD CMR America', Minerva, 2002, 40 (2), forthcoming.
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improvement in altitude tolerance (though these latter results were confounded by
the strong temperature dependence of absolute ceiling in mice). Together the whole
set of results suggested that Compound E and related adrenal cortex hormones
affecting carbohydrate metabolism would not improve pilot performance, and al-
though hormone treatment might have some limited utility in preventing death at
extreme high altitudes, the right training regimen would be at least as effective. Nor
did the physiological experiments testing the possibility of using cortical steroid
treatmentstopreventshockyieldpromisingresults. RichardsandtheCMReffectively
pulled the plug, discontinuing physiological research aimed at assessing the value of
cortical steroid usage in the combat theatre (though the hormones continued to play
a role in some other medical research projects, for example on convalescence and
healing). The negative assessment of the military potential of the hormones was
reflected in the declassification of the physiological research involving them, in late
1943.28
All the chemistry groups had been pursuing methods of synthesizing Kendall's
Compound A from various sterol starting materials, since this steroid had carbo-
hydrate metabolism activity like Compound E and similar, though simpler, structure.
Presumably, Compound E would be easily synthesized from A, or by a related
pathway, once this was developed. But by the spring of 1943, the chemists had made
very limited progress in their quest to plant an oxygen on the carbon 11 summit of
the steroid nucleus. With the shadow on the future ofthe synthetic projects cast by
the findings of the physiologists, Mansfield Clark naturally inquired as to whether
the CMR wanted the chemists' research to continue after June 1943. Richards
discussed the matter with Bush, and replied that while specific chemical projects
would have to be judged on a case-by-case basis, the CMR and Bush agreed that
the effort to synthesize the cortical hormones should continue. The rationale for this
decision is curious. As Richards put it in a letter to Clark:
It is obviously impossible to say with conviction that the problem is one of direct military
significance. It is equally impossible to say that it is not. What I have said above [i.e. that
chemical work should proceed] is based on the possibility that military significance may
emerge and upon the conviction that the work as it is proceeding is definitely in the national
interest.29
Why the chemists' work was "definitely" in the national interest during wartime
whether or not cortical hormones might have military applications is an intriguing
question. Naturally, the hormones were intellectually interesting to a number oflife
scientists, but the OSRD's purpose was precisely to divert scientists away from purely
intellectual goals, and toward wartime priorities. Rather than military or scientific
interest in these hormones, the primary consideration behind continuation of the
28[Richards and C N H Long], n.d., 'Special box 36, USNA227/29. Louis Flexner,
Appraisal ofAdrenal Projects in CAM', folder 'Reclassification ofAviation Medicine Reports', 28
'Adrenal Cortex', box 9, USNA 227/165. On Oct. 1943, folder42, carton 12, Richards Papers.
shock, see W WSwingle, March 1943, 'Final 29Richards to Clark, 1 May 1943, USNA 227/
Technical Progress Report', contract OEMcmr-5, 165, box 9, folder 'Adrenal Cortex'.
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work might well have been protecting the position of the American pharmaceutical
industry in the coming peace. Bush, active in industrial policy and experienced in
consulting since his early career in electrical engineering, would have been as aware
of the commercial importance of methods to produce a new class of drugs as
Richards, longtime consultant to Merck. And there was no secret that Reichstein
was forging ahead, backed by European drug firms. While most American firms did
not actually begin advertising their post-war consumer product lines until mid-1944,
the issue ofthe post-war economy would never be far from the minds ofsuch urbane
men, even while immersed in serving the nation's war effort.
At any rate, later in 1943 the chemists received the unwelcome news, via Clark
from the Swiss firm CIBA (Reichstein's industrial partner after Holland fell under
German occupation), that Reichstein had beaten them all in the race to synthesize
Compound A. As Kendall put it, there were "whispers" and "raised eyebrows" that
the cortical hormone biochemists had made so little headway in two years, while
their counterparts working on penicillin and anti-malarials had all made such
excellent progress. Most of the chemists on Clark's team (with the exception of
Gallagher, who was making good progress by a route different from Kendall's)
quickly discontinued theircontract projects, asmight beexpected. But even in March
1944 Richards was willing to allow continuation of the synthetic projects despite a
"growing disposition within the CMR to regard the prospects ofpractical usefulness
from the adrenal cortex contracts as remote", asking Clark to reconfirm which
synthetic projects he thought were especially worthwhile.30 The indefatigable Kendall
had naturally soldiered on through Reichstein's triumph, and in January 1944
gleefully reported to his Research Corporation contacts that he had developed a
newsyntheticpathwaytoCompoundAwithupto 1000timestheyieldofReichstein's.
Kendall passed his new method on to Merck immediately, and the firm set out to
manufacture at least 5 grams of Compound A so that there would be sufficient
material to evaluate the hormone as a drug. Through the rest of 1944 Kendall
continued at the Mayo to improve the Compound A method and to seek a pathway
to Compound E, now under less favourable conditions as he became less able to
protect his laboratory personnel from the draft, especially after Clark's chemical
committee officially disbanded in mid-1944. He continued sharing detailed in-
formation with Merck chemists by mail, laboratory personnel were exchanged
between Mayo and Rahway, and Kendall himselfvisited to consult with the firm in
person. In late December 1944, Merck chemist Lewis Sarett, who had been working
on the project since the beginning of the Mayo-Merck collaboration, surprised
Kendall by achieving synthesis of Compound E, albeit in small quantities and at
low efficiency. The Merck chemists who had undertaken the large batch synthesis of
Compound A by Kendall's method, Jacob van de Kamp and S M "Monty" Miller,
3'Kendall, op. cit., note 6 above, p. 103. continued through March 1945, Wallis's was
Richards to Clark, 18 March 1944, folder 'Adrenal continued to December 1944, and both Fieser's
Cortex', box9, USNA 227/165; Hans Clarke to and Bergmann's werecontinued only to June 1944;
Charles Keefer, with attached Kendall memo, 4 see record sheets on contracts OEMcmr-42,
April 1945, folder 'Kendall, E. C.', box46, USNA OEMcmr-32, OEMcmr-168, and OEMcmr-106
227/165. Gallagher's OSRD contract was respectively, folder 51, carton 12, Richards Papers.
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impressed Kendall still more when at the end of 1945 they produced 97 grams of
Compound A instead ofthe planned 5 grams, by efficiency improvements in several
steps.3' Thus, as the war ended, Kendall seemed on the brink of reaching his
long-time goal of making the pure cortical hormones he studied available as
pharmaceuticals.
Clinical trials and further physiological experimentation ensued immediately at
the start of 1946. Confident that Compound A, so similar to (though weaker than)
his favoured Compound E in carbohydrate activity, would yield impressive results,
Kendall organized a special symposium to present the findings at Atlantic City
just before the annual meeting there of the Federation of American Societies for
Experimental Society. A record of the exact proceedings of the symposium seems
not to exist, but, judging by the researchers involved, reports were presented on the
effectiveness ofCompound A in counteracting bacterial toxins, in treating Addison's
disease, and perhaps in other endocrine disorders. Whatever precisely was reported,
the overall impression of those involved was entirely negative. One of Kendall's
associates purportedly remarked to him immediately after the event that it should
never have been allowed to happen, because now no drug company would be willing
to invest in Compound E.32 But Sarett persevered through 1945 and 1946 and,
incorporating process improvements made by Kendall and the other Merck chemists
as he learned ofthem, in 1947 found an economical route to synthesize Compound
E-that is, as it now was dubbed, "cortisone". Merck promptly set about producing
a large batch, supplying the material for the famed 1948 clinical trial in which
patients long crippled by rheumatoid arthritis walked (indeed, danced) with ease
again, leading to the 1950 Nobel Prize to Kendall, along with Reichstein and Philip
Hench, Kendall's rheumatologist colleague. The Research Corporation negotiated a
patent pool among Kendall, Merck, CIBA, and other holders ofrights to key steps
in the industrial cortisone synthesis process so that the commercialization of the
hormone could proceed. While cortisone itselfwas soon replaced by derivatives with
fewer side-effects, the cortical steroids were a permanent benefit to medicine, and an
important tool in the further elucidation of the endocrine system.33
3' Kendall to Poillon, 15 Jan. 1944, folder
'Research Corporation', box 8, Kendall Papers.
Kendall, op. cit., note 6 above, ch. 11.
32Kendall, op. cit., note 6 above, ch. 11.
Kendall to Major, 11 Feb. 1946, 23 Feb. 1946,
and 4 March 1946, all in folder 'Abbott
Laboratories', carton 8, Kendall Papers. For
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material (typhoid vaccine)', FASEB Proc., 1946,
5: 163; Eleanor Venning and J S L Browne,
'Excretion ofurinary corticoid hormones by man
in health and disease', FASEB Proc., 1946, 5: 159.
3 On Kendall and Sarrett's continuing work,
see, for example, Kendall to Major, 1 April 1944;
Kendall to Major, 6 April 1944; Major to
Kendall, 13 July 1944; van de Kamp to Kendall,
10 Aug. 1944; Kendall to Major, 15 Aug. 1944;
Kendall to van de Kamp, 2 Dec. 1944; Sarrett to
Kendall, 13 Dec. 1944; all in folder 'Merck and
Company Correspondence 1943-1944-1945',
carton 8, Kendall Papers. On the patent
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The anti-inflammatory properties which quickly made cortisone the archetypical
post-war miracle drug had been discovered through Hench's clinical intuition, and
the fact that such applications not been anticipated by endocrinologists studying
Compound E in animal models certainly demonstrates the limits oflaboratory-based
drug development research. Intriguingly, however, the use of 1930s-style whole
cortical extracts to boost strength and to combat mental stress and fatigue, the pre-
war market for the remedy which must have shaped pharmaceutical companies'
expectations of the indications drugs like cortisone would acquire, continued into
the 1970s, due mainly to a medical movement promoting the extracts as a cure for
hypoglycaemia (which, according to this faction, was much more widespread than
orthodox opinion held).3 Thus may the misbegotten dreams of master molecules
die hard, particularly when they take such a perennially attractive form as a remedy
bringing happiness and strength. But this is a story for another day.
Conclusion
The story of research on the hormones of the adrenal cortex well illustrates the
degree to which, in the 1910s through the 1940s, hormones were taken to be master-
controllers oflife processes (in the case ofthese particular hormones, ofrespiratory
efficiency, circulation, and a variety of neural functions). It also shows how much
the harnessing of hormones was thought to offer medicine through mastery over
these same processes, and how thoroughly the interest in practical applications
could draw hormone researchers into intimate relationships with the pharmaceutical
industry-relationships more than slightly resembling those decried by recent critics
ofmolecular biologists' involvement with biotechnology firms.35 While, unlike some
entrepreneurial biologists today, the hormone researchers of the early twentieth
century generally did not personally grow rich from their patents, their corporate
partners did, and their universities acquired income to support their activities.
Kendall and his generation ofendocrinological researchers drew money andmaterial
resources from industry to support their research, for which they exchanged the
intellectual propertyrightstheyacquiredinthecourseoftheirscientificinvestigations.
These resources could be crucial for the advancement of their endocrinological
34For the enthusiastic reception of cortisone,
see G Hetenyi, Jr, and J Karsh, 'Cortisone
therapy: a challenge to academic medicine in
1949-1952', Perspect. Biol. Med, 1997, 40:
426-39; Harry Marks, 'Cortisone, 1949: a year
in the political life of a drug', Bull. Hist. Med.,
1992, 66: 419-39; and David Cantor, 'Cortisone
and the politics of drama, 1949-1955', in J V
Pickstone (ed.), Medical innovations in historical
perspective, New York, St Martin's Press, 1992,
pp. 165-84. For the post-war notoriety of
cortical extracts, see, for example, 'Medical
groups decry useless injections for nervous
women', J. Am. med Ass., 1973, 223: 682; and
Joel Yager and R T Young, 'Non-hypoglycemia
is an epidemic condition', N. Engl. J. Med,
1974, 291: 907-8.
3 Edward E Yoxen, Thegenebusiness: who
shouldcontrolbiotechnology?, NewYork, Oxford
University Press, 1983; Martin Kenney,
Biotechnology: theuniversity-industrial complex,
New Haven, Yale University Press, 1986; idem,
'Biotechnology and the creation ofa neweconomic
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research, costly and pressed for time by competition as their research programmes
often were. Furthermore, industrial partnerships represented much more than simply
resources for scientists pursuing knowledge of hormones, if their ambitions also
included the introduction oftheir hormone discoveries into medical practice. To this
end, endocrinology researchers had to become active partners in the commercial
endeavours of their drug company collaborators, acting in their partner's interests
with respect to factors affecting the firm's likely return on investment from hormone
drug development, such as avoiding patent obstacles and pursuing maximal yields
in the hormone preparation methods they were developing, and maintaining the
secrecy of unpatentable proprietary information.36 And as Kendall's 1950 Nobel
Prize reminds us, such work was not regarded as scientifically inferior because of its
commercial dimensions, according to the values ofhis day. However, one might well
observe that Kendall was a man of his era, and that his day was passing both
literally (in that he would retire within a year of receiving the Nobel prize) and
figuratively. He was among the last of his particular breed of entrepreneur.
Kendall's style of entrepreneurship had served him well in the Depression. It will
also be evident from this story that it served him well enough during the Second
WorldWar, government intervention causing no majorinterruption in his industrially-
oriented hormone discovery and drug development programme. Perhaps the OSRD
forced Kendall to take on a corporate partner earlier in the game than he would
have in peacetime, but Merck was an ideal match for him, and he suffered no crucial
loss either ofintellectual property orpersonal scientific credit as a result ofgovernment
involvement in his cortical hormone work. The discontinuation of OSRD interest
in his project caused even less interruption than its initiation. This finding of
continuity through the war comes as something ofa surprise ifone expects, following
many historians of science, that government management of science during wartime,
in the United States particularly by the OSRD, suddenly transformed academic
physical and biomedical sciences alike into the "Big Science"-richly funded,
bureaucratized, technology-intensive, large in scale, and mission-oriented in style
(often with a mission related to military or industrial applications)-that became so
widespread after the war. This is not the place for a general assessment of the impact
ofwartime governmentpatronage onlife sciences inAmerica, but Kendall's experience
suggests that in fields where "Big Science" was already the rule through pre-war
industrial sponsorship, agencies like the OSRD did little beyond allowing the
competitive and productive forces already in play to take their course. Certainly
Bush, Richards, and Clark were solicitous of the interests of Kendall and his
industrial partners at every stage of the game, from their initial decision to let
3 Kendall plainly shows all of these pathway with higher yields than that obtained by
behaviours, for instance in his continuing his collaborator Sarett. His concern to keep
research during 1943-44 on Compound A proprietary information secret from competitors
synthesis in pursuit of a different pathway, with was evinced by his successful efforts to limit
higher yields, than that already developed (and information exchange among the OSRD
patented) by Reichstein, and by his continued collaborators on Compound E, described above.
pursuit in 1945 of a Compound E synthesis See Kendall, op. cit., note 6 above, ch. 11.
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Kendall keep his patent application and other competitive information secret from
other participants in the cortical steroid project, to their decision to allow Kendall
the special privileges of a CMR contractor well beyond their mid-1943 conclusion
that his hormones were unlikely to contribute to the war effort. Perhaps this should
come as no surprise, since Bush was no socialist, and accomplishing national goals
through the voluntary participation of private enterprise was his agency's essential
strategy for recruiting science to the war effort.37
Though Kendall's cortical hormone work through the 1930s and 1940s illustrates
how well established industrially-sponsored "Big Science" already was before the
war in certain fields of biomedical research holding promise for pharmaceutical
companies, in the post-war era the expansion of government patronage did bring a
real change to the character of research even in these precocious fields. In 1950,
when the National Science Foundation was finally established in the United States
after years of debate on its exact form, the annual research budget of the National
Institutes of Health had already exceeded the entire wartime budget of the CMR
and was doubling every year or two.38 In this new era, federal funding for basic
research quickly overshadowed what was available from private enterprise, and the
industrial collaborations that allowed Kendall to do technology-rich and labour-
intensive work on a grand scale through three decades became unnecessary for the
biomedical generation that followed his. The rising influence of government science
agencies in the 1950s brought the peer-reviewed grant to dominance and, until
recently, discouraged industrial collaborations, at least in biomedical science. It is
to the post-war science agencies that we must look to explain some aspects of the
discontinuities that appear, in hindsight, to have been brought to science by the
Second World War. Much historical work remains to be done on these agencies and
their influence in the life sciences in the post-war period.39 But notwithstanding these
changes thatmadepeer-reviewed government funding the rule, anddespite theeclipse
of the hormone by the gene in the second half of the twentieth century, we must
recall that earlier age when entrepreneurial life scientists like Kendall reigned
37 For a fuller treatment of life science during
the war, see Rasmussen, op. cit. note 27 above.
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supreme-an age which included the war years themselves-ifwe wish to learn any
lessons that this past might teach us about our current preoccupations with today's
master molecules. The first such lesson might be that industrial collaborations do
not always represent an insuperable obstacle to biomedical research of the highest
calibre.
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